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Summary: It has been reported that patients with vascular disease seem to increase their concentration of plasma
homocysteine after the acute episode, whereas reexamined control subjects do not change their concentration of
plasma homocysteine over time. Since the main determinants of plasma homocysteine are serum cobalamin, blood
folate and serum creatinine we measured these quantities in 20 control subjects and 49 stroke patients in the acute
phase and at reexamination 1.5—2 years after acute stroke onset. There were no significant differences between the
levels of blood folate, serum cobalamin and serum creatinine in the acute and convalescent phase of all 49 stroke
patients. However, we noted a significant decrease of blood folate concentrations in a subgroup of patients (n = 25)
who had increased plasma homocysteine concentrations. Thus the increase in plasma homocysteine concentrations
in this group of patients may partly be caused by a marginal folate deficiency.
Introduction
Greatly elevated plasma levels of homocysteine, a sul-
phydryl amino acid, are found in subjects with homo-
cystinuria (1). These patients exhibit early arteriosclero-
sis, and arterial and venous thrombosis. Numerous
studies have indicated that milder hyperhomocysteinae-
mia is also associated with increased risk of occlusive
vascular diseases (2—7). Homocysteine is the demethy-
lated derivative of methionine (1), and can be metabo-
lized by two pathways, either catabolized by the trans-
ulphuration pathway to cysteine or remethylated to me-
thionine, mainly by the folate and vitamin B12 depen-
dent enzyme methionine synthase. Homocysteine
accumulates when methionine synthase is impaired.
Plasma levels of homocysteine have also been shown to
be elevated in patients with cobalamin deficiency and
folate deficiency (8—14). Genetic factors such as hetero-
zygosity for homocystinuria or the thermolabile variant
of methylenetetrahydrofolate reductase seem to partly
explain the aetiology of hyperhomocysteinaemia. Also a
possible relation between diet, hyperhomocysteinaemia
and arteriosclerosis has recently been suggested (15).
However, little is known about the extent to which a
marginal vitamin deficiency contributes to mild hyper-
homocysteinaemia and vascular disease.
In an earlier study (16) we showed that the concentration
of plasma homocysteine is significantly increased in
stroke patients 1—2 years after the acute stroke onset,
whereas reexamined control subjects showed no change
in their concentration of plasma homocysteine over a
similar period of time. Similar findings of increased
plasma homocysteine in the post-acute phase of myocar-
dial infarction (17, 18) have been reported. We also ob-
served that plasma homocysteine concentrations do not
change in the convalescence phase in patients (4) or over
time in control subjects (19). In earlier studies (19, 20)
we found that the main determinants of plasma homo-
cysteine in healthy subjects are age, serum cobalamin,
blood folate and serum creatinine. In the present study
we therefore measured the concentrations of serum co-
balamin, blood folate and serum creatinine in 20 control
subjects and 49 stroke patients in the acute phase and at
reexamination 1.5—2 years after acute stroke onset.
Materials and Methods
Study populat ion
In the present study we reexamined 49 patients and 20 control
subjects from earlier study populations (16, 20) 1.5—2 years after
the first examination. The patients were randomly selected from a
consecutive series of 172 patients with stroke (16). The patient
group consisted of 44 patients with cerebral infarction and 5 pa-
tients with intracerebral haemorrhage (31 males and 18 females
aged 66 ± 10 years). Likewise, the control subjects were randomly
selected from the 244 control subjects described earlier (20), who
had been randomly selected from the local population records. The
control group consisted of 14 males and 6 females aged 66 ± 8
years. We also analysed the concentration of plasma homocysteine,
blood folate, serum cobalamin and serum creatinine in 41 males
and 41 females (aged 65 ± 16 years) randomly selected from the
larger control population (20).
Assays
Blood samples for determination of total plasma homocysteine
were collected in evacuated tubes containing EDTA at about 8 a. m.
after an overnight fast and centrifuged within 15 minutes at 3000g
for 5 minutes. Both patients and control subjects were allowed at
least 10 minutes of recumbent rest before blood sampling on the
first occasion, whereas patients and control subjects at reinvestiga-
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tion were allowed 10—15 minutes rest in a sitting position before
venipuncture. The plasma was stored at —70 °C until analysis. To-
tal plasma homocysteine (the sum of all homocysteinyl moieties,
whether in sulphydryl or disulphide forms, free or protein-bound)
was measured as previously described (21) by HPLC after reduc-
tion of disulphide bonds with dithiothreitol and deproteinization
with sulphosalicylic acid. The method has a coefficient of variation
of 4%, calculated at the level of 15 μιηοΐ/ΐ.
Serum cobalamin and blood folate levels were determined by ra-
dioassay, using purified intrinsic factor and purified folate binding
protein, at the Department of Clinical Chemistry, University Hospi-
tal, Lund (Vitamin B12/Folate Dual RIA kit, Amersham, UK). The
reference interval for serum cobalamin is 110—650 pmol/1 and for
blood folate 125—500 nmol/1. Serum creatinine (upper reference
limit 120 μιηοΐ/ΐ) was assayed with routine methods at the Depart-
ment of Clinical Chemistry.
Statistics
The results are presented as means and SD. All statistical tests were
two-tailed and the 5% level of significance was used to evaluate the
results. Mann- Whitney U test was used in the case of two independent
samples and Spearman's rank correlation coefficients were calcu-
lated to test for monovariate relationship between different variables.
Results
The initial/reinvestigated mean values and SD of the
concentrations of plasma homocysteine, blood folate, se-
rum cobalamin and serum creatinine are given in table
1. The concentration of plasma homocysteine in control
subjects did not change between the acute and convales-
cent phase, whereas that in patients increased signifi-
cantly. The patients were divided into two groups (tab.
1). One group consisted of patients whose plasma homo-
cysteine had increased by more than 2 μηιοΙ/1 between
the two analyses. This group showed a significantly de-
creased concentration of blood folate at reinvestigation.
The other group of patients had similar plasma homo-
cysteine concentrations (±2.0 μηιοΙ/1) on both occa-
sions. In this group there were no significant changes
between the initial values of blood folate and the values
at reinvestigation. Compared with the large group of
healthy control subjects there were no significant devia-
tions in the concentrations of blood folate, serum cobal-
amins or serum creatinine in any of the investigated
groups (tab. 1).
Correlations between the initial values and the values at
reinvestigation of each quantity in all patients were also
analysed. Plasma homocysteine ρ = 0.66, ρ < 0.001),
serum creatinine (p = 0.65, ρ < 0.001) and blood folate
(p = 0.61, ρ < 0.001) correlated highly significantly be-
tween the two analyses, whereas serum cobalamin
(p = 0.31, p < 0.05) exhibited a lower degree of corre-
lation.
The initial concentration of plasma homocysteine in all
patients correlated significantly with the corresponding
concentrations of serum creatinine (p = 0.46, p < 0.01)
and serum cobalamins (p = —0.33, p < 0.05), whereas
there was no significant relation between the concentra-
tions of plasma homocysteine and blood folate
(p = — 0.17, p > 0.05). The correlation between plasma
homocysteine concentrations and age was significant
(p = 0.27, p < 0.05). At reinvestigation the concentra-
tion of plasma homocysteine in all patients correlated
significantly with the corresponding concentrations of
serum creatinine (p = 0.40, p < 0.01) and blood folate
(p = —0.40, p < 0.01), whereas there was no significant
relation between plasma homocysteine and serum cobal-
amin (p = —0.21, p > 0.05). The correlation between
plasma homocysteine concentrations and age was signif-
icant (p = 0.43, p < 0.01).
Tab. 1 The concentrations of plasma homocysteine, blood folate, serum cobalamin and serum
creatinine in different groups of control subjects and patients. Mean and SD are given.
Plasma
homocysteine
(μηιοΙ/1)
Blood
folate
(nmol/1)
Serum
cobalamin
(pmol/1)
Serum
creatinine
(μηιοΙ/1)
Control subjects (n = 82)
Control subjects (n = 20)
Initial values
Reinvestigation
All patients (n = 49)
Initial values
Reinvestigation
13.8 ±4.6
14.0 ± 4.5
12.6 ± 3.8
12.6 ± 4.3
15.4 ± 4.8"
Patients with increased plasma homocysteine > 2.0 μιηοΐ/ΐ (η = 25)
Initial values 11.5 ±2.9
Reinvestigation 17.5 ± 4.3***
Patients with unchanged values ± 2.0 μηιοΐ/l (η = 18)
Initial values 12.4 ± 4.1
Reinvestigation 13.0 ± 4.2
356 + 178
400 + 211
348 ± 168
366 ± 154
327 ± 136
399 ± 191
317 ± 152*
329 ± 94
329 ± 104
254 ± 109
290 ± 101
280 ± 101
245 ± 72
299 ± 136
245 ± 75
274 ± 114
256 ± 60
317+ 141
+ 24
90 + 16
84 ± 13
79 ± 19
83 ± 16
78 + 20
84+ 18
77 ± 19
81 ± 16
* p < 0.05; p < 0.01; p < 0.001 compared to initial values.
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Discussion
The increase of plasma homocysteine in the convales-
cent phase after an acute vascular event, as reported
earlier (16, 17, 18) and as observed in the present study,
might depend on lowered values at the time of the acute
vascular event and/or an increase of plasma homocyste-
ine levels in the convalescent phase. It is known that
the acute inflammatory episode includes a number of
systemic changes, e.g. dramatic increases of hepatic
acute phase response plasma proteins and decreased
synthesis of albumin. Since the major part of plasma
homocysteine is bound to albumin, the binding of
plasma homocysteine to protein may be decreased at the
time of the acute vascular event. This leads to a higher
renal clearance of homocysteine and possibly also to
increased metabolic (hepatic) bio-availability, thereby
eliminating homocysteine from plasma. That plasma ho-
mocysteine is lowered in the acute vascular event of
a myocardial infarction is supported by the findings of
Egerton et al. (18). These authors reported an approxi-
mate 25% decrease in plasma homocysteine during the
acute phase response of the plasma proteins, compared
with plasma homocysteine after the acute phase re-
sponse had dissipated (> 7 days). In the present study
there was no significant correlation between blood folate
and plasma homocysteine at the time of the acute vascu-
lar episode, which might therefore be explained by the
temporary lowering of the plasma homocysteine concen-
trations during this episode.
Conceivably, the increased plasma homocysteine level
in the convalescent phase could be due to a real increase
after the vascular event. The reason for such an increase
is not obvious. In our earlier study (16) of 17 stroke
patients there were no significant differences between
the values for blood folate, serum cobalamin and serum
creatinine in the acute and convalescent phases. We ob-
tained similar results in the present study of all 49 stroke
patients. However, we noted a significant decrease of
blood folate concentrations in the subgroup of patients
(n = 25) who increased their plasma homocysteine con-
centrations. Thus the increase in plasma homocysteine
concentrations in this group of patients may partly be
caused by the decrease of blood folate concentrations,
since there is an intimate relationship between plasma
homocysteine concentrations and folate status (8—14).
That plasma homocysteine concentrations are affected
by folate status in the convalescence phase is also sup-
ported by the correlation between plasma homocysteine
and blood folate at reinvestigation. The reason for de-
creased blood folate concentrations at reinvestigation is
not obvious but it is known that several types of chronic
inflammatory disorders lower blood folates (22). It is
possible that the arteriosclerotic process in stroke pa-
tients has a similar influence on blood folates. Another
possibility might be a change of lifestyle (less physical
activity and/or poorer nutrition) after the stroke event,
with a decreased folate intake.
Numerous studies have indicated that elevated plasma
homocysteine concentrations are associated with
increased risk of premature occlusive vascular diseases
(2—7). Genetic factors such as heterozygosity for homo-
cystinuria or the thermolabile variant of methylenetetra-
hydrofolate reductase seem to largely account for the
aetiology of hyperhomocysteinaemia. A possible rela-
tion between diet, hyperhomocysteinaemia and arterio-
sclerosis has recently been suggested (15). However,
little is known about the extent to which a marginal vita-
min deficiency contributes to mild hyperhomocysteinae-
mia and vascular disease. Recently Seihub et al. (23)
analysed plasma homocysteine in 1160 elderly subjects.
The mean plasma homocysteine concentration was
increased in subjects within the lowest deciles of serum
cobalamin and blood folate. These results suggest that
marginal vitamin deficiencies are associated with hyper-
homocysteinaemia. Their findings also indicated that el-
evated plasma homocysteine concentrations and subop-
timal folate status were associated with an increased risk
of carotid artery stenosis in elderly people. The observa-
tion (23) that the prevalence of carotid artery stenosis
among the subjects in the lowest folate quartile re-
mained significantly elevated even after adjustment for
plasma homocysteine concentrations may indicate an in-
dependent effect of folate deficiency on atheroma for-
mation and subsequent carotid artery stenosis. Recently,
it was also demonstrated that inadequate folate intake
was the main determinant of the homocysteine-related
increase in carotid artery wall thickening (24). Further-
more, Pancharuniti et al. (25) have reported that low
folate concentrations, but not serum cobalamin concen-
trations, are associated with coronary artery disease. The
significant association between folate and vascular dis-
ease can probably be largely explained by its regulation
of plasma homocysteine concentration.
In conclusion, the observation by Egerton et al. (18) and
the findings of the present study indicate that the
increased plasma homocysteine in the convalescent
phase after an acute vascular event might be partly due
to a lowering effect of plasma homocysteine at the time
of the acute episode, and partly due to the fact that a
marginal folate deficiency develops in many patients in
the convalescent phase. It may therefore be of value for
these patients to receive folate supplementation in the
convalescent phase.
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